Metabolic syndrome and prostate cancer

References

• Hubbard JS, Rohrmann S, Landis PK et al. Association of prostate cancer risk with insulin, glucose and anthropometry in the Baltimore longitudinal study of aging. Urology63, 253–258 (2004).
   PubMed Web of Science ®Google Scholar
• Amling CL. Relationship between obesity and prostate cancer. Curr. Opin. Urol.15, 167–171 (2005).
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes37, 1595–1607 (1998).
   Google Scholar
• Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes41, 715–722 (1992).
   PubMed Web of Science ®Google Scholar
• WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Part 1: Diagnosis and Classification of Diabetes. Volume 52. WHO, Geneva, Switzerland (1999).
   Google Scholar
• Balkau B, Charles MA, Drivsholm T et al. European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of the insulin resistance syndrome. Diabetes Metab.28, 364–376 (2002).
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report on the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Hsing AW, Gao YT, Chua S Jr, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer. J. Natl Cancer Inst.95, 67–71 (2003).
   PubMed Web of Science ®Google Scholar
• Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ323, 334–336 (2001).
   PubMed Web of Science ®Google Scholar
• Stattin P, Kaaks R. Re: insulin resistance and prostate cancer risk. J. Natl Cancer Inst.95, 1086–1087 (2003).
   PubMedGoogle Scholar
• Hammarsten J, Hogstvedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press.13, 47–55 (2004).
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur. J. Cancer41, 2887–2895 (2005).
   PubMed Web of Science ®Google Scholar
• Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol. Biomarkers Prev.13, 1646–1650 (2004).
   PubMed Web of Science ®Google Scholar
• Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am. J. Epidemiol.164, 1094–1102 (2006).
   PubMed Web of Science ®Google Scholar
• Lund Håheim L, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am. J. Epidemiol.164, 769–774 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology68, 1198–1205 (2006).
   PubMed Web of Science ®Google Scholar
• Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur. Urol.51, 199–206 (2007).
   PubMed Web of Science ®Google Scholar
• Hammarsten J. Benign prostatic hyperplasia and clinical prostate cancer – two new components of the metabolic syndrome. Curr. Hypertens. Rev.2, 301–309 (2006).
   Google Scholar
• Prezioso D, Denis LJ, Klocker H et al. Estrogens and aspects of prostate disease. Int. J. Urol.14, 1–16 (2007).
   PubMed Web of Science ®Google Scholar
• Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L. Risk factor for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol. Biomakers Prev.6, 863–873 (1997).
   PubMed Web of Science ®Google Scholar
• Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology65, 1168–1172 (2005).
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Bub JD, Uzuki M, Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem. Biophys. Res. Commun.333, 79–87 (2005).
   PubMed Web of Science ®Google Scholar
• Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell–adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J. Biol. Chem.278, 42660–42667 (2003).
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Banu J, Rahman M, Causey J, Fernandes G. Biological effects of conjugated linoleic acids in health and disease. J. Nutr. Biochem.17, 789–810 (2006).
   PubMed Web of Science ®Google Scholar
• Boyd DB. Insulin and cancer. Integr. Cancer Ther.2, 315–329 (2003).
   PubMedGoogle Scholar
• Garber K. IGF-1: old growth factor shines as new drug target. J. Natl Cancer Inst.97, 790–792 (2005).
   PubMed Web of Science ®Google Scholar
• Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol. Res.55, 233–244 (2006).
   PubMed Web of Science ®Google Scholar
• Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br. J. Cancer94, 1221–1225 (2006).
   PubMed Web of Science ®Google Scholar
• Amling CL. The association between obesity and the progression of prostate and renal cell carcinoma. Urol. Oncol.22, 478–484 (2004).
   PubMed Web of Science ®Google Scholar
• Campbell KL, McTiernan A. Exercise and biomarkers for cancer prevention studies. J. Nutr.137, 161S–169S (2007).
   PubMed Web of Science ®Google Scholar
• Kaaks R, Lukanova A. Effects of weight control and physical activity in cancer prevention: role of endogenous hormone metabolism. Ann. NY Acad. Sci.963, 268–281 (2002).
   PubMed Web of Science ®Google Scholar
• Moore MA, Park CB, Tsuda H. Physical exercise: a pillar for cancer prevention? Eur. J. Cancer Prev.7, 177–193 (1998).
   PubMed Web of Science ®Google Scholar
• Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur. J. Clin. Invest.35, 290–304 (2005).
   PubMed Web of Science ®Google Scholar
• Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome. Obes. Rev.3, 303–308 (2002).
   PubMedGoogle Scholar
• Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol. Metab. Clin. North Am.33, 283–303 (2004).
   PubMed Web of Science ®Google Scholar